Last Updated: May 16, 2024


Featured Articles

Behind the counter: Switching to injectables for HIV

Medical News Today | March 13, 2024

One-pill-a-day HIV treatments

aidsmap | December 2023

Drug Pricing Advisory Boards: What They Are and Why They Matter to Patients

HIV/HCV Watch | July 2023

Long-Acting, Injected HIV Meds Can Help Tough-to-Treat Patients | July 5, 2023

2023 Treatment Guide: Dealing With HIV Med Side Effects? | July 3, 2023

Updates to HIV Clinical Guidelines on Prevention and Treatment of Opportunistic Infections | June 28, 2023

A Treatment Timeline

POZ Magazine | January 17, 2023

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV 

Gilead | December 22, 2022

FDA Approves SUNENCA (lenacapavir) for Adults with Limited Treatment Options

FDA | December 22, 2022

Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

POZ | December 8, 2022

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel

JAMA. 2022; doi:10.1001/jama.2022.22246. [epublished online December 1, 2022]

Exciting alternatives: An overview of long-acting HIV treatment, prevention

Healio | October 2022

American Academy of HIV Medicine Launches Long-Acting Agent Resource Center

American Academy of HIV Medicine | August 22, 2022

Long-acting Agent Resource Center website

HIV LAA | August 2022

2022 HIV Drug Chart

POZ | June 27, 2022

12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry

Sintered Filter | May 10, 2022

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV | January 20, 2022

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

News Updates

HIV Preexposure Prophylaxis (PrEP)

National HIV Curriculum | May 6, 2024

Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People...

NIH | May 1, 2024

Caution advised when prescribing long-acting injectable cabotegravir and rilpivirine to avoid drug resistance

Aidsmap | April 30, 2024

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

GILEAD | April 26, 2024

Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment

The New York Times | April 17, 2024

More evidence that PrEP works as well for women

Aidsmap | April 17, 2024

Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection

AAFP | April 2024

FDA Approves Dovato for Teens Living With HIV | April 10, 2024

FDA approves dolutegravir/lamivudine to treat HIV infection in adolescents

Contemporary Pediatrics | April 8, 2024

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons...

Oxford Academic - Oxford University Press | April 6, 2024

Understanding HIV drug resistance, implications for treatment strategies 

PharmaNewsIntelligence | March 25, 2024

Many Americans Are Unaware of HIV Prevention Medication

KFF | March 20, 2024

New drug candidates show promise to reverse HIV immune evasion

News Medical | March 19, 2024

U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

Johnson & Johnson | March 19, 2024

HIV Medications 101

AETC | March 19, 2024

People who struggle with daily HIV regimen should be offered long-acting injections

Healio | CROI 2024 | March 9, 2024

Investigational two-drug regimen safe, effective for patients with HIV

Healio | CROI2024 | March 6, 2024

PrEP use up, HIV incidence down, data show

Healio | CROI2024 | March 5, 2024

Dolutegravir-Based ART Efficacious for HIV Management Through 192 Weeks

Infectious Disease Advisor | March 13, 2024

Semaglutide Reduces Liver Fat in People Living With HIV

POZ | March 13, 2024

Ultra-Long-Acting Cabotegravir Could Be Given Every Four Months

POZ | March 11, 2024

New treatment options for critically important WHO fungal priority pathogens 

Clin Microbiol Infect. 2024 Mar 8:S1198-743X(24)00118-6. doi: 10.1016/j.cmi.2024.03.006

Examining a Newer Therapy for Heavily Treated HIV Patients

Contagion Live | March 7, 2024

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead | March 5, 2024

New report documents increase in HIV drug resistance to dolutegravir

WHO | March 5, 2024

New HIV Drugs on the Horizon (webinar)

IAS-USA | February 19, 2024

Antiretroviral Medications and Initial Therapy

National HIV Curriculum | February 11, 2024

2024 Session: Florida may allow pharmacists to prescribe HIV prevention drugs

Tallahassee Democrat | February 9, 2024

Do Higher PrEP Costs Affect Risk for Subsequent HIV Infection?

NEJM | January 29, 2024

How Does Smoking Affect People with HIV? | January 26, 2024

Enhancing quality of life and medication adherence for people living with HIV: the impact of an information system

NIH | January 23, 2024

New Antibiotic Effective Against Drug-Resistant Bacteria, Study Indicates

CNN | January 3, 2024

Longer-Lasting HIV Meds Are on the Horizon

POZ | December 26, 2023

Preexposure Prophylaxis to Prevent Acquisition of HIV

American Family Physician | December 2023

Expert: The Evolution of HIV Care, Treatment Options, How Pharmacists Can Assist in Providing Care

Pharmacy Times | December 18, 2023

Why taking your HIV treatment properly is important

aidsmap | December 2023

Hospitals are abusing this drug discount program

Washington Blade | December 8, 2023

Considerations for long-acting antiretroviral therapy in older persons with HIV 

AIDS. 2023 Dec 1;37(15):2271-2286. doi: 10.1097/QAD.0000000000003704. Epub 2023 Nov 16.

NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic | November 14, 2023

Risk Factors for Dolutegravir Resistance Identified in Patients With HIV

Infectious Disease Advisor | November 14, 2023

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

The Lancet | November 2023

Quality of Life of People Living with HIV on Antiretroviral Therapy

Dove Medical Press | November 10, 2023

Commercial Determinants of Access to HIV Preexposure Prophylaxis

JAMA | November 10, 2023

Rukobia Still Effective at Five Years for People With Drug-Resistant HIV

POZ Magazine | November 8, 2023

Implementation of Long-Acting Drugs for Treatment and Prevention of HIV

IAS-USA | November 2023

Trial Shows Limited Resistance to Sunlenca in Patients with HIV 

Managed Healthcare Executive | October 23, 2023

2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV 

Contagion Live | October 21, 2023

Single High-Dose Liposomal Amphotericin B Safe for HIV-Associated Fungal Infections

Infectious Disease Advisor | October 19, 2023

IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP 

Patient Care Online | October 15, 2023

Pre-Exposure Prophylaxis | September 28, 2023

Another class of cancer drugs may contribute to curing HIV

Aidsmap | September 18, 2023

Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?

NEJM | September 25, 2023

Clinicians Weigh In on the Benefits of Rapid Antiretroviral Therapy for HIV in EDs

Infectious Disease Advisor | September 22, 2023

Can a Shot to Prevent HIV Make a Dent in America’s Epidemic?

US News | September 21, 2023

Doxycycline Improves Outcomes of Early Syphilis in Patients With HIV 

Infectious Disease Advisor | September 20, 2023

Two-drug antiretroviral regimens for HIV

The BMJ | September 1, 2023

Lenacapavir: Drug Offers New Hope for Multi-drug Resistant HIV

Yale School of Medicine - Yale University | August 30, 2023

HIV Virologic Suppression Maintained After Switch to Long-Acting ART 

Infectious Disease Advisor | August 30, 2023

Overcoming HIV Drug-Resistance Mechanisms

Infectious Disease Special Edition | August 18, 2023

MSF refuses to sign ViiV's last-minute NDA for access to most-effective HIV prevention drug CAB-LA 

MSF Access Campaign | August 17, 2023

PrEP use and HIV incidence among youth at-risk for HIV infection in Los Angeles and New Orleans: Findings from ATN 149 

J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003272.

Switch to Dolutegravir/Lamivudine Works Well Despite Resistance Mutations

POZ Magazine | August 11, 2023

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and...

NIH | August 8, 2023

Immune-modulating medication may help clear HIV reservoir

Aidsmap | August 5, 2023

More Time on Dolutegravir Needed Before Drug Switch: Study

Medscape | August 4, 2023

Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine | July 30, 2023

Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis 

NIH | July 27, 2023

How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy

The New York Times | July 22, 2023

Walmart Opens 70 More HIV-Focused Pharmacies

POZ Magazine | July 7, 2023

USFDA gives tentative approval to Lupin's HIV/AIDS drug

The Financial Express | July 4, 2023

Gilead prevails in $3.6 billion antitrust trial over HIV meds

Courthouse News Service | June 30, 2023

The HIV-1 capsid core is an opportunistic nuclear import receptor

Nature Communications | June 24, 2023

Second-Line Switch to Dolutegravir for Treatment of HIV Infection

New England Journal of Medicine | June 2023

What happens to HIV drugs in the body, and do missed doses matter?

Aidsmap | June 2023

Real-world data confirm the efficacy of dolutegravir-based dual therapy

Aidsmap | May 29, 2023

Interest Grows in Long-Acting Injectables for HIV Treatment

Pharmacy Times | March 17, 2023

Implementing Long-acting Injectable PrEP with an Eye Toward Equity: Yale's Dr. LaRon ... | March 2, 2023

New HIV Treatment and PrEP Guidelines

POZ Magazine | February 13, 2023

Sunlenca Looks Great for Highly Drug-Resistant HIV. Will It Serve a Broader Purpose? 

TheBody | January 31, 2023

Baseline Resistance to Second-Generation INSTIs, First-Line NRTIs Unlikely in HIV 

Infectious Disease Advisor | January 30, 2023

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 

Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.


  2019 Archives 2020 Archives 2021 Archives 2022 Archives